HCWB HCW Biologics Inc

$HCWB HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T Cells

$HCWB Company showed in studies that CAR-T cells manufactured using HCW11-006 as a reagent exhibited strong anti-tumor activity and enhanced antiviral potency as well as potential for lowering the cost of production of CAR-T therapies

$HCWB invest in AMFN It is Bitcoin 2.0 for investors. Be part of something special and get rich. Very rich. Be part of the first company which will commercialize electricity produced from fusion process.

$HCWB HCW Biologics Strengthens U.S. Patent Estate for Its Lead Clinical-Stage Immunotherapeutic HCW9302 as Alopecia Areata Treatment

$HCWB — SILENCED ON REDDIT FOR EXPOSING SHORT MECHANICS! 🚨🐻Reddit mods deleted this DD after 6K views. Why? Because the mathematical noose around shorts at $2.20 is real:1️⃣ DRY FLOAT: Total active worldwide float is a mere 387,682 shares. They are running completely out of physical ammunition.2️⃣ 463% CTB: Maintaining the cap is financial suicide. Shorts are burning a fortune in a 463% annual borrow fee just to keep the lid on.3️⃣ THE TRAP: Proposal 1 is their escape hatch. They need retail to abstain on Nov 17 to print 600K warrants to cover their short position (56% of float).THE PLAN: Vote ACTIVE AGAINST to freeze those warrants forever under Nasdaq Rule 5635(d). Armistice gets completely TRAPPED at a physical 4.99% baseline alongside retail, forcing them to protect our shares to save themselves.RECORD DATE: SEPT 21. Get your 16-digit control number from IBKR. No abstentions (Ex. 3.2 quorum trap). VOTE AGAINST PROP . Market physics are absolute when supply is ZERO

$HCWB Mechanics: Price artificially frozen vs science (TOBI/TRBC, 100% Alopecia Q4, Akron cashflow). • Float: 169K(split)+218K(July)=387,682 total shares. • Short Ammunition: Fund shorted 100% physical shares; only 135,001 left in magazine. • Cost: Crushing 463% borrow fee. Financial suicide for shorts. • The Shield: Fund holds 600K common warrants. Want retail to abstain Nov17 Special Meeting (Prop 1) to dilute 23% and shield shorts against Q4 data. Objective: Keep price depressed. 🎯 TIMELINE: 1. Record Date (Sept 21): Hold shares to vote. 2. Nasdaq Compliance (Sept 22): End delisting monitoring. 100% eligible for institutions. 3. Prop 1 (Oct 1): Get 16-digit control code from broker. VOTE NO (Rule 5635d) to kill the 600K warrants. No warrants = shorts (56% of total float) left naked. When Q4 data hits pre-market, HFT algorithms will forced-buy chasing zero supply. Do not hand them your shares. 🚀💎

🚨 $HCWB INSIDER SCAM EXPOSED: Akron CAR-T Revenues Hidden To Force Predatory 58% Dilution! 🚨 Retail shareholders are completely defenseless. Executive insiders and affiliated hedge funds now control MORE THAN 60% of the voting power, turning the October 27 Special Meeting into a total corporate sham.Connect the dots of this premeditated asset-stripping scheme:1️⃣ The Akron Deception: On Sept 4, management signed an exclusive contract with Akron Biotech for CAR-T reagents (HCW11-006), securing immediate organic revenues. Instead of disclosing this to protect the stock, they HID it to launch the predatory Proxy dilution on Sept 8, intentionally crushing the price to scare retail ("shaking out the paper").2️⃣ The Asset Laundering: They moved the worldwide rights of HCW11-006 and the multi-billion Alopecia drug (HCW9302) to Beijing Trimmune JV for pennies ($3.5M cash) while forcing US public holders to fund the cash-burning trials of HCW11-08B and HCW11-040 under a bankruptcy

$HCWB — Volume + momentum watch Scanner flagged a fresh move at $2.53. +2.43% price momentum 4.79x normal volume 32.8K volume on the move candle Watching $2.50 hold/confirmation for potential continuation. Volume expansion is the key here.

$HCWB announces an exclusive distribution agreement with Akron Biotech for its HCW11-006 cell-therapy reagent.

$HCWB HCW Biologics supplies research and cGMP-grade HCW11-006 and Akron markets and distributes the reagent to its established network of research institutions and commercial companies